WallStSmart

Novartis AG ADR (NVS)vsOneMedNet Corp. (ONMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 4292616% more annual revenue ($56.58B vs $1.32M). NVS leads profitability with a 23.9% profit margin vs -254.3%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

ONMD

Avoid

13

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: -73.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued
ONMDUndervalued (+75.0%)

Margin of Safety

+75.0%

Fair Value

$2.34

Current Price

$0.77

$1.57 discount

UndervaluedFair: $2.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

ONMD0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

ONMD4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$36.83M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-29.9%2/10

Revenue declined 29.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : ONMD

ONMD has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : ONMD

The primary concerns for ONMD are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a declining stock while ONMD is a turnaround play — different risk/reward profiles.

ONMD carries more volatility with a beta of 1.12 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 13/100), backed by strong 23.9% margins. ONMD offers better value entry with a 75.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

OneMedNet Corp.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

OneMedNet Corporation develops technology that focuses on accessing and sharing health data. The company is headquartered in Eden Prairie, Minnesota with a development office in Vancouver, Canada.

Want to dig deeper into these stocks?